Really, friend DDD24, this is not a sensible statement at all.
We don't know what the CR rate for CF33 will be. The clinical trials started at what Prof Fong described as a "Teeny Tiny dose" because that's what the FDA demanded. There was never an expectation that the very low doses would result in a CR. We are still in dose escalation, and expecting that the OBD will be declared soon, but the most recent patient data is from much earlier in the dose escalation process.
We are now at the levels Prof Fong hoped would show good results. Let's wait and see what those results are, both in mono therapy and in combination with pembrolizumab. Let's also see more data on the results with Cholangiocarcinoma - where CF33 achieved very promising early results.
Making up a CR rate based on the results of dose escalation is simply unscientific and meaningless - and especially so in this case, given the trivial starting dosage.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)